Clinical Response and Glucocorticoid Sparing With JAK Inhibitors in Takayasu Arteritis: A Disease-Specific Systematic Review and Meta-analysis. (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1123; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Primary outcomes were overall response rate (ORR) and change in prednisone-equivalent glucocorticoid dose at 6 and 12 months. In TAK, JAK inhibition was associated with high clinical response rates and clinically meaningful glucocorticoid reduction, with limited reported safety signals. The current evidence is driven mainly by small observational Asian cohorts and is strongest for tofacitinib, while baricitinib data remain limited and no TAK-specific upadacitinib evidence was identified. These findings support JAK inhibition as a plausible steroid-sparing strategy in selected patients with active or refractory TAK, but standardized prospective studies incorporating vascular imaging outcomes are needed to define its role more precisely."
Retrospective data • Review • Herpes Zoster • Inflammation • Varicella Zoster • Vasculitis
|
|
Roxana González Mazarío1; Jorge Juan Fragío Gil2; Pablo Martínez Calabuig3; Mireia Sanmartin Martinez4; Ivan Jesus Lorente Betanzos1; Berta Gomez Correas1; Pablo Garcia Castro1; Amalia Rueda Cid1; Juan Jose Lerma Garrido1; Isabel Martinez Cordellat1; Cristina Campos Fernández1
|